Intersect ENT Announces Publication of a Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps

Intersect ENT^®, Inc. (NASDAQ: XENT), a company dedicated to
transforming care for patients with ear, nose and throat conditions,
today announced publication of a pooled analysis of the RESOLVE and
RESOLVE II randomized controlled trials (RCT) in the American
Journal of Rhinology & Allergy. The results provide level 1a
clinical evidence supporting the use of the SINUVA^®
(mometasone furoate) Sinus Implant for management of patients with
recurrent nasal polyps in adult patients who have had previous ethmoid
sinus surgery.

The analysis included 375 patients with chronic sinusitis and nasal
polyps who were candidates for revision endoscopic sinus surgery (RESS)
because of persisting symptoms of nasal obstruction/congestion and
recurrent bilateral nasal polyps (non-cancerous tissue growth) despite
ongoing topical steroid therapy and a recent course of systemic
steroids. Patients were randomized to undergo an in-office bilateral
placement of SINUVA in the ethmoid sinuses under local anesthesia
(treatment group) or an in-office bilateral sham procedure (control
group). All patients were required to use mometasone furoate nasal spray
(MFNS) once daily. All study patients were blinded during the baseline
procedure and each follow-up endoscopic examination.

The pooled analysis met all four efficacy endpoints, demonstrating a
decrease in nasal obstruction/congestion score (p=0.0095), bilateral
polyp grade (p=0.0008) and ethmoid sinus obstruction (p<0.0001) at 90
days in SINUVA patients compared to the control group on MFNS alone.
Additionally, results revealed a 59% reduction in the proportion of
SINUVA patients who were still indicated for RESS at day 90 compared to
a 31% reduction among patients in the control group (p<0.0001). Only one
patient (0.4%) experienced an implant-related serious adverse event
(epistaxis).

“The findings of this analysis reveal the favorable role SINUVA can play
in the management of recurrent nasal polyps in patients who have had a
previous sinus surgery,” said Pablo Stolovitzky, M.D., of ENT of Georgia
in Atlanta, lead author of the study. “These data provide clinical
evidence that SINUVA – administered through a quick and simple office
procedure – offers significant benefits for patients, reducing polyp
growth and nasal obstruction, and ultimately, reducing the need for
repeat surgeries.”

Intersect ENT will sponsor several events at RhinoWorld Chicago from
June 5 to 9. To learn more about SINUVA, visit Booth #18.

SINUVA was approved by the U.S. Food and Drug Administration (FDA) in
December 2017. Placed during a routine office visit under local or
topical anesthesia, SINUVA is designed to deliver an anti-inflammatory
steroid directly to the site of disease for an extended period of time
(up to 90 days) following placement into the sinus cavity.

“We are very pleased to see these strong study findings added to the
foundational pool of data supporting the use of SINUVA,” said Lisa
Earnhardt, president and CEO, Intersect ENT. “We are proud that this
data provides further evidence for ENTs seeking improved outcomes for
patients with nasal polyps and supports SINUVA as a favorable
alternative to revision endoscopic sinus surgery.”

About the RESOLVE Study

RESOLVE was a double-blind RCT in 100 adult patients with chronic
rhinosinusitis and nasal polyps, who had a previous sinus surgery and
were indicated for revision endoscopic sinus surgery because they
presented with recurrent nasal obstruction/congestion symptoms and
recurrent bilateral sinus obstruction due to nasal polyps. The study
evaluated the safety and efficacy of SINUVA to improve symptoms of nasal
obstruction/congestion and reduce nasal polyps over three months.
RESOLVE showed positive trends and an acceptable safety profile but did
not meet its efficacy endpoints. The reduction in nasal
obstruction/congestion score and bilateral polyp grade from baseline to
day 90 reached statistical significance in a subset of patients with a
higher polyp burden (grade 2 or higher on each side).

About the RESOLVE II Study

RESOLVE II was a double-blind RCT in 300 adult patients with chronic
rhinosinusitis and nasal polyps who had a previous sinus surgery but
were indicated for revision endoscopic sinus surgery because they
presented with refractory symptoms of nasal obstruction/congestion and
recurrent bilateral nasal polyps. The study evaluated the safety and
efficacy of SINUVA over three months. Primary efficacy endpoints were a
change in nasal obstruction/congestion score from baseline to 30 days
and in bilateral polyp grade from baseline to 90 days. The SINUVA
treatment group included 201 randomized patients who underwent bilateral
placement of SINUVA in the ethmoid sinuses. Ninety-nine patients were
randomized to the control group where they received a sham procedure.
Patients receiving SINUVA demonstrated statistical improvements compared
to the control group across multiple prespecified primary and secondary
efficacy endpoints.

About Steroid Releasing Sinus Implants

Steroid releasing implants provide targeted delivery of an
anti-inflammatory steroid directly to the site of disease. Placed during
a routine doctor’s office visit with local or topical anesthesia, the
SINUVA^® (mometasone furoate) Sinus Implant is designed to
deliver a treatment for nasal polyp disease for adults who have had
prior ethmoid sinus surgery. The American Rhinologic Society (ARS)
endorsed the utilization of drug eluting sinus implants in 2016, citing
the number of well-controlled studies on drug-eluting implants in the
paranasal sinuses.

About Intersect ENT^®

Intersect ENT is dedicated to transforming ear, nose and throat care by
providing innovative, clinically meaningful therapies to physicians and
patients. The company’s steroid releasing implants are designed to
provide mechanical spacing and deliver targeted therapy to the site of
disease. In addition, Intersect ENT is continuing to expand its
portfolio of products based on the company’s unique localized steroid
releasing technology and is committed to broadening patient access to
less invasive and more cost-effective care.

For additional information on the company or the products including
risks and benefits please visit www.IntersectENT.com.
For more information about SINUVA, please visit www.SINUVA.com.

Intersect ENT is a registered trademark and SINUVA is a trademark of
Intersect ENT, Inc.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR
THE SINUVA SINUS IMPLANT

INDICATION

SINUVA^® Sinus Implant is a prescription steroid-releasing
(mometasone furoate) implant indicated for the treatment of nasal polyps
in patients 18 years or older who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

Who should not use SINUVA?
Do not use SINUVA if you are
allergic to mometasone furoate or any ingredients of the implant.
What
should I tell my doctor before receiving SINUVA?
Before you
receive SINUVA, tell your doctor about all medical conditions you have
including nasal/sinus problems (such as nasal ulcers or trauma), eye
problems (such as glaucoma or cataracts), or any untreated fungal,
bacterial, or viral infections.

What are the possible side effects of SINUVA?
Serious
side effects of SINUVA can include:
Local reactions including
nosebleed and injury to nerves or blood vessels in the nose/sinus.
Serious
allergic reactions have happened in patients using mometasone
furoate including rash, itching or swelling of the lips, face, tongue,
and throat, and breathing problems. Call your doctor right away if you
have any of these reactions.
Weakened immune system that may
increase your risk of infections. Avoid contact with people who have
contagious diseases such as chickenpox or measles. Call your doctor
right away if you have been near someone with chickenpox or measles.
Adrenal
insufficiency is a condition in which the adrenal glands do not make
enough steroid hormones and can cause tiredness, weakness, nausea and
vomiting and low blood pressure. Talk to your doctor if steroid effects
such as Cushing Syndrome and adrenal suppression appear.
The
most common side effects of SINUVA (in more than 1% of subjects and
that occurred more frequently in the treatment group compared to
control) in clinical studies were bronchitis, cold symptoms, middle ear
infections, headache, lightheadedness or dizziness, asthma, and
nosebleeds. Tell your doctor if you have any side effects that bother
you or don’t go away.
Risks related with the insertion and removal
of SINUVA are similar to other endoscopic sinus procedures.

SINUVA is made from materials designed to soften over time and may fall
out of the nose on its own as polyps decrease or if you sneeze or blow
your nose forcefully. The implant can be removed 90 days after placement
or earlier at your doctor’s discretion. Repeat use of SINUVA has not
been studied.

Contact your doctor immediately if you have any changes in
vision, excessive nasal bleeding, symptoms of infection or symptoms
suggesting that the implant has moved, such as irritation or a choking
sensation in the back of the throat.

You are encouraged to report negative side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.

For important risk and use information, please see Full Prescribing
Information for SINUVA at www.sinuva.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of
Sections 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements should not
be read as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which such
performance or results will be achieved. These statements include those
related to the safety, efficacy and patient and physician adoption of
SINUVA. These forward-looking statements are based on Intersect ENT’s
current expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as
a result of these risks and uncertainties, which include, without
limitation the company’s ability to procure and maintain required
regulatory approvals for our products and the adoption of SINUVA and the
company’s other therapies by physicians and patients, as well as other
risks detailed from time to time in Intersect ENT’s filings with the
Securities and Exchange Commission (SEC), including Intersect ENT’s
filings on Form 10-K and Form 10-Q available at the SEC's Internet site (www.sec.gov).
Intersect ENT does not undertake any obligation to update
forward-looking statements and expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005890/en/